British Institute of International and Comparative Law, Twelfth CLF Meeting – Remedies, November 30, 2005, London, England

I. INTRODUCTION

On 19 October 2005, the Canadian Competition Bureau (the "Bureau") issued in draft an information bulletin (the "Draft Bulletin") describing its approach to designing and implementing merger remedies under the Canadian Competition Act (the "Act").1 According to a press release issued with the Draft Bulletin, interested parties have until 20 January 2006 to comment, following which time the Bureau will consider the feedback provided and publish a final document. 2

Although the Draft Bulletin is generally consistent with the Bureau's past public statements concerning merger remedies, it reflects the Bureau's clear intention to circumscribe in its favour the process involved in implementing such remedies. This is undoubtedly the result of perceived failures to implement effective or timely remedies in previous merger cases.

II. THE LEGISLATIVE CONTEXT

Section 92 of the Act authorizes the Commissioner of Competition (the "Commissioner"), who heads the Bureau, to challenge merger transactions that are likely to "prevent or lessen competition substantially" in a relevant market. Applications to challenge mergers are brought by the Commissioner before the Competition Tribunal (the "Tribunal"), a hybrid administrative body comprised of both judges and non-judicial members. The Tribunal may issue orders preventing a merger from being consummated, dissolving the merger or imposing a remedy requiring the disposition of specific assets or shares. With the consent of the parties, the Tribunal may also issue orders requiring that "any other action" be taken in respect of a merger by the person against whom the order is directed.

The Commissioner has only rarely exercised the authority to challenge merger transactions before the Tribunal. In the approximately 19 years since the Act's merger provisions were enacted, only four mergers have been the subject of contested applications. To the extent that issues are raised by a merger, they are generally resolved through some form of negotiated settlement between the Commissioner and the merging parties.

The Supreme Court of Canada has held that the standard against which a merger remedy is to be judged is whether the remedy will "restore competition to the point at which it can no longer be said to be substantially less than it was before the merger".3 In other words, the remedy need not go so far as to bring the relevant market back to its pre-merger state of competition; it only needs to eliminate the "substantial lessening or prevention of competition" caused by the merger in that market. The Court also has stated that a merger remedy should be the least intrusive avenue possible to achieve the desired effect. However, if the only choice is between a remedy that goes further than is strictly necessary and one which does not go far enough even to reach the acceptable level, the former must be preferred.

III. THE DRAFT BULLETIN

The purpose of the Draft Bulletin is to set out the "essential elements" that the Bureau will take into account in "all cases where remedial action is required". While the remedy in any given situation will depend upon the specific facts of that case, the Bureau will insist in all instances that the remedy's terms are sufficiently clear and well-designed to ensure timely implementation, with minimal or no future monitoring or enforcement by the Bureau or the Tribunal. Remedies must also be designed to "promote competition, not competitors".

The key points of the Draft Bulletin are summarized below.

Negotiation Rather Than Litigation

The Draft Bulletin re-affirms the Bureau's clear preference for negotiating merger remedies without resort to litigation. The Draft Bulletin states that proceeding by way of settlement is less costly, more expeditious and allows a wider range of remedies to be considered.

By virtue of amendments to the Act in 2002, most merger settlements in Canada are now concluded in the form of a "consent agreement" that is registered with the Tribunal. The new consent agreement procedure does not require prior approval from the Tribunal. Rather, upon registration, a consent agreement is deemed to have the same force and effect as if it were an order of the Tribunal. 4

Structural versus Behavioural Remedies

The Draft Bulletin reiterates past statements by the Bureau about its strong preference for structural merger remedies (i.e., divestitures of assets or businesses). 5 According to the Draft Bulletin, structural remedies are simpler, more effective, less costly to administer and more readily enforceable than behavioural remedies. For these reasons, the Bureau will consider stand-alone behavioural remedies only where no viable structural remedy is available. 6

Nonetheless, the Draft Bulletin leaves open the possibility of accepting what it calls "quasistructural" remedies in lieu of divestitures where such remedies have a significant structural impact by reducing or eliminating barriers to entry, offering access to necessary infrastructure or key technology, or otherwise facilitating new entry or expansion. Examples include licensing intellectual property, granting non-discriminatory access rights to networks and supporting the removal or reduction of tariffs. The Bureau will only accept these types of "quasi-structural" remedies if they adequately address the competitive harm arising from the merger (e.g., eliminate significant entry barriers) and do not create any anti-competitive effects of their own.

For the most part, though, the Draft Bulletin states that the Bureau is inclined to accept behavioural remedies only where they support a "core structural remedy", e.g. by assisting the buyer of the divested assets to become a more effective competitor more quickly or by imposing additional behavioural restraints on the acquiring party post-merger. Examples include shortterm supply agreements, technical assistance, waiver of restrictive contract terms and codes of conduct. 7

The Divestiture Process

Given the Bureau's clear preference for structural remedies, most of the Draft Bulletin is dedicated to describing the Bureau's requirements in negotiating such remedies.

According to the Draft Bulletin, the Bureau will agree to a negotiated divestiture remedy only if it meets the following minimum criteria:

  • the assets elected for divestiture must be viable and sufficient to eliminate the substantial lessening of competition;
  • the divestiture must occur in a timely manner; and
  • the buyer of the assets must be independent of the merged entity and have the ability, incentives and intention to compete effectively in the relevant market(s).

The Bureau will also not normally agree to permit closing to take place before a remedy is agreed upon, e.g., pending completion of its investigation.8

(i) The Divestiture Package

The Bureau may accept either "full" divestitures of entire operating businesses or "partial" divestitures of discrete assets like manufacturing facilities, retail locations, individual product lines or intellectual property. However, the Bureau will apply greater scrutiny to partial divestitures since the competitiveness of discrete business components is more speculative.

Whether a divestiture is full or partial, the Bureau prefers a "clean sweep" of assets from one of the merging parties – usually the target – in order to reduce uncertainty and asset integration issues and to limit the ability of the acquiring party to obtain confidential information about the assets to be divested. In addition, the Bureau may require the divestiture of assets outside the relevant market, particularly where economies of scale or scope are important or when assets in the relevant market do not constitute a stand-alone business.

Prior to agreeing to an asset package, the Bureau also may conduct confidential market testing to determine whether the assets to be divested will be saleable, viable and effective in eliminating the competitive harm arising from the merger. This could involve seeking information from competitors, customers, suppliers and industry experts.

In order to ensure the viability of the divestiture package, the Bureau will normally require the acquiring party to "hold separate" the assets or businesses that are the subject of the remedy pending implementation of the divestiture. In such cases, the Bureau will also normally require that an independent "hold separate manager" be appointed to operate the assets until the sale is complete. Only in very limited circumstances will the Bureau settle for a mere "maintenance" obligation in respect of the relevant divestiture assets, i.e., directing the acquiring party to maintain the competitive viability of the divestiture assets without the benefit of a hold separate arrangement. Vendors also will be expected to provide all reasonable and ordinary commercial representations and warranties to the buyer as part of any divestiture package.

(ii) Timely Implementation

The past several years have seen a number of high profile cases in which negotiated structural remedies were not implemented because no buyers could be found for the divestiture package. In the result, the assets reverted to the acquiring party notwithstanding that – at least on the Bureau's analysis – this resulted in a substantial lessening of competition. 9

In yet other cases, the acquiring parties, after having entered into divestiture agreements with the Bureau, subsequently sought to rescind these agreements based on changed circumstances. 10 In one of these cases, the Bureau suffered a significant loss when the Tribunal agreed to rescind the agreement, holding that the Bureau's inflexibility in pursuing the initial remedy despite evidence of significant imminent entry by a competitor marked a failure in its obligation to take into account changing market realities. 11

Not surprisingly, therefore, the Draft Bulletin strongly favours "fix-it-first" solutions, which would involve divestiture of relevant assets to an approved buyer prior to or upon completion of the merger. In the Bureau's view, this is the preferred approach because it avoids issues regarding the marketability of a divestiture package, prevents material devaluation of the relevant assets, and preserves or restores competition in the relevant market as quickly as possible. 12

The same concern about ensuring implementation underscores the Bureau's approach to postmerger divestiture remedies. These remedies ordinarily provide for a fixed period of time in which the vendor can market the divestiture package on the best terms it can negotiate with potential buyers. Where a sale is not effected in the initial period, an independent trustee will be appointed to complete the sale.

One requirement the Bureau says it will now impose in this regard is to give vendors only three to six months in which to divest the asset package before a trustee will be appointed to take over the process. This period is shorter than the initial sale periods in past merger settlements which have typically varied between six months and one year. According to the Draft Bulletin, the Bureau may grant a short extension of the initial sale period in "exceptional circumstances" or where there is a binding letter of intent and closing of the divestiture transaction is "clearly imminent". The trustee sale period will also normally be 3-6 months, depending on the circumstances.

The Draft Bulletin states that the Bureau also will not agree to any settlement that imposes restrictions on the price at which the trustee may sell the designated assets, regardless of how those restrictions may be expressed (e.g., "fair market value", "going concern", "liquidation price", "fire sale", etc.). 13

In addition, the Bureau may require "crown jewel" provisions that would allow specified assets to be added to or substituted for the initial divestiture package to make the sale more appealing to buyers during the trustee sale period. According to the Draft Bulletin, crown jewel provisions are not intended to be punitive but rather to encourage vendors to implement the initial divestiture package quickly and to ensure a viable alternative remedy if the initial package is not saleable. 14 The Draft Bulletin provides little guidance about when the Bureau will require crown jewels except to say that the Bureau is more likely to use crown jewel provisions to support the effective implementation of partial divestitures.

(iii) Suitable Buyers

The Draft Bulletin states that the Bureau will not approve a proposed buyer unless it has both the means and incentive to preserve or restore competition. In particular, the Bureau will insist that:

  • sale of the assets to the buyer must not itself harm competition;
  • the buyer must be at arm's length from the vendor; and
  • following divestiture, the assets must be used by the buyer to compete in the relevant market (as judged in part on the buyer's business plan).

Thus, while the universe of acceptable buyers generally includes new and existing market participants, the latter may not be appropriate where the Bureau's concerns about the merger relate to coordinated behaviour among existing firms in the market. The Bulletin also notes that in the case of partial divestitures, where the assets lack an established infrastructure, the Bureau may require the vendor to identify the buyer for pre-approval even before agreeing to register a consent divestiture agreement.

Confidentiality

As a concession to vendors, the Draft Bulletin notes that the Bureau may agree to keep some of the key terms of a consent divestiture agreement confidential during the sale period, e.g., the length of the initial sale period, the specific assets that form part of a crown jewel package (but not the existence of such a package) and the fact that the sale is not subject to a minimum price. However, given the Bureau's clearly articulated position on these very issues in the Draft Bulletin, it would appear that the promise of confidentiality may have only a marginal impact on preserving the bargaining position of vendors during the initial sale period. In any event, the Bulletin makes clear that all terms of a consent agreement will be made public if and when the trustee sale period begins.

Bureau Oversight

The Bureau will oblige vendors to provide written reports on a regular basis with respect to the progress of their divestiture efforts. The Bureau will also normally require the appointment of an independent third party "monitor" when either hold separate or maintenance provisions are part of the remedy to ensure that vendors are fulfilling their obligations under the consent agreements. The monitor will also be required to report to the Bureau. Similarly, if the sale process becomes the responsibility of a trustee, the trustee will be required to report to the Bureau on a regular basis concerning all efforts to accomplish the sale. The Bureau will also retain the right to interview officers, directors, employees and agents of the merging parties, as necessary, to ensure compliance with the consent agreement.

Where there is disagreement over the interpretation of the terms of a consent agreement, the Bureau may apply to the Tribunal for clarification. If, however, the Bureau is of the view that there has been clear and wilful disregard of the agreement, the Bureau will take appropriate enforcement steps. 15

International Mergers

The Draft Bulletin contains a separate section discussing the Bureau's approach to remedying the anticompetitive effects in Canada resulting from international mergers. When a merger leads to similar anticompetitive effects in Canada and other jurisdictions, the Bureau will coordinate with other competition authorities on remedies. Coordination may involve ongoing communication as developments arise in particular jurisdictions, participation in joint discussions with merging parties and the creation of parallel remedies to ensure consistency across jurisdictions.

According to the Draft Bulletin, cooperation on remedies will be helpful where a single buyer, trustee or monitor is required for a North American or global divestiture. In addition, and consistent with past Bureau practice, the Draft Bulletin notes that the Bureau may determine in appropriate cases that action beyond that taken by foreign jurisdictions is not required. 16 On the other hand, the Bureau will be more likely to formalize its own remedies in Canada when the merger raises Canada-specific issues, the assets to be divested reside in Canada or remedial action in Canada is critical to enforcing the terms of the settlement.

V. CONCLUSION

There are few surprises in the Draft Bulletin. As an example, the Draft Bulletin is very similar in content to the European Commission's notice on merger remedies. 17

That said, the Draft Bulletin makes clear and formalizes the Bureau's intention to narrow the scope for negotiation of merger remedies and to place even more emphasis on the rapid implementation of divestiture packages. In particular, the short three to six month window within which vendors will be permitted to market a divestiture package before losing control of the process is a departure from past practice. This development, combined with the Bulletin's emphasis on "fix-it-first" remedies, "crown jewels" and "no minimum price" provisions, is aimed at avoiding drawn-out divestiture periods.

A possible further indication that the Bureau intends to narrow the scope for negotiating divestiture agreements is its plan to include a "template consent agreement" with the final version of the Draft Bulletin. This template would reflect the "standard guiding principles" set out in the Draft Bulletin. It is presently unclear whether such a template would merely be a point of reference in remedy negotiations or whether merging parties would effectively be expected to adopt the template in every case. The latter would represent an unfortunate development. Both policy considerations and practical realities dictate that in dealing with merger remedies, as with most other aspects of competition law, the Bureau must be flexible rather than dogmatic in its approach.

1 Competition Act, R.S.C. 1985, c. C-34.

2 The Draft Bulletin and the Bureau's press release are available at http://www.competitionbureau.gc.ca/internet/index.cfm?itemID=1983&lg=e.

3 Canada (Director of Investigation and Research) v. Southam Inc. (1997), 71 C.P.R. (3d) 417 (S.C.C.).

4 Competition Act, R.S.C. 1985, c. C-34, section 105. Prior to 2002, the Commissioner also made frequent use of informal "undertakings" to settle merger cases notwithstanding that undertakings are not provided for in the Act. These undertakings typically consist of a written commitment by the acquiring party to engage in certain actions (e.g., divest assets or shares) in order to resolve the Commissioner's concerns about the merger in question. However, after the new consent agreement process was adopted, Bureau officials stated that they would no longer be willing to rely on undertakings to resolve merger concerns and would insist on consent agreements being registered with the Tribunal. As a result, the Commissioner has publicly accepted undertakings in just one case since the 2002 amendments came into force. See Gaston Jorré, Senior Deputy Commissioner of Competition, "Remedies Panel", Remarks to the Canadian Bar Association's 2002 Annual Fall Conference on Competition Law, Ottawa, Ontario (October 3-4, 2002). See also OECD, Directorate for Financial and Enterprise Affairs Competition Committee, Merger Remedies, DAF/COMP (2004) 21 (December 2004) at 126.

5 Over 90% of the Bureau's merger resolutions between 1995 and 2002 involved some form of structural remedy.

6 For a recent example of a merger settlement in which the Bureau did accept remedies that were entirely behavioural in nature, see Commissioner of Competition v. British Columbia Railway Company and Canadian National Railway Company (CT-2004-008). The consent agreement between the Commissioner and the acquiror, Canadian National Railway ("CN"), contained a complex series of commitments by CN to maintain competitive rates and service levels for shippers in the affected markets. The Bureau also agreed to accept pricing commitments as part of the merger settlement, which is very rare. Significantly, however, the consent agreement provided for an arbitration mechanism to deal with potential disputes between CN and shippers over rates, which meant that the Bureau would not need to be involved in ongoing monitoring and enforcement of these issues. In addition, by virtue of the acquisition, the B.C. Rail line became subject to the concurrent jurisdiction of the federal regulator of transportation services, including with respect to rates.

7 For examples of merger remedies incorporating these types of behavioural remedies, see, e.g. Commissioner of Competition v. Bayer AG (CT-2002-003) and Commissioner of Competition v. ADM Agri- Industries Ltd. (CT-1997-002) – supply agreements; Commissioner of Competition v. Trilogy Retail Enterprises L.P/Chapters (CT-2001-003) and Commissioner of Competition v. Astral Media Inc., Télémédia Radio Inc. and Radio Média Inc. (CT-2001-010) – codes of conduct; Reitmans/Shermax (June 2, 2002), http://www.competitionbureau.gc.ca/internet/index.cfm?itemID=410&lg=e – waiver of restrictive covenants.

8 But cf two merger cases in which the Bureau permitted closing to take place before it had completed its review: Commissioner of Competition v. Tolko Industries Ltd. (CT-2004-012) and Commissioner of Competition v. Westway Holdings Canada Inc. (CT-2003-001). In both cases, the acquiring parties agreed to hold separate the acquired business until the Bureau had completed its review.

9 See Canada (Commissioner of Competition) v. Trilogy Retail Enterprises L.P. (CT-2001-003); Canada (Commissioner of Competition) v. Abitibi-Consolidated Inc. (CT-2001-009), http://www.cttc. gc.ca/english/CaseListing.asp?x=68; and undertakings given by Air Canada with respect to its acquisition of Canadian Airlines, http://www.competitionbureau.gc.ca/internet/index.cfm?itemID=619&lg=e.

10 See RONA Inc. v. Commissioner of Competition (CT-2003-007) and United Grain Growers Limited v. Commissioner of Competition (CT-2002-001), http://www.ct-tc.gc.ca. These applications were brought pursuant to section 106 of the Act, which provides that "[t]he Tribunal may rescind or vary a consent agreement or an order….. on application by the Commissioner or the person who consented to the agreement, or the person against whom the order was made, if the Tribunal finds that the circumstances that led to the making of the agreement or order have changed and, in the circumstances that exist at the time the application is made, the agreement or order would not have been made or would have been ineffective in achieving its intended purpose."

11 RONA Inc. v. Commissioner of Competition, 2005 Comp. Trib. 18., supra. For a discussion of this decision, please see Mark Katz, Charles Tingley and Elisa Kearney, "Merger Settlements in Canada: Recent Developments", North American Corporate Lawyer, Volume VIII, No. 3 (2005).

12 For a case involving a "fix-it-first" situation, see, e.g., Canada Bread/Multi-Marques (October 12, 2001), http://www.competitionbureau.gc.ca/internet/index.cfm?itemID=533&lg=e.

13 This position is the result of the Bureau's negative experiences in several past cases. In Air Canada, supra, for example, the divestiture was required to be made at "fair market value"; no buyer could be found. In Abitibi, supra, the Bureau faced litigation over the interpretation of a provision that prohibited the trustee from making a sale at a price and on terms that equated "to those of a 'going out of business', 'fire' or 'liquidation sale'". Ultimately, no sale was ever made.

14 For an example of the use of a "crown jewel" provision ,see, e.g., Bayer AG, supra note 7.

15 For example, section 66 of the Act makes it a criminal offence to contravene an order of the Tribunal.

16 For example, the Bureau recently determined that divestitures required by the United States and European competition authorities with respect to Procter & Gamble's acquisition of Gillette adequately resolved concerns in Canada. See http://www.competitionbureau.gc.ca/internet/index.cfm?itemID=1953&lg=e.

17 Commission Notice on remedies, Official Journal C 68, 02.03.2001, pages 3-11.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.